Kodiak Sciences Inc. (KOD) News
Follow Kodiak Sciences Inc. (KOD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Shares of pharmaceutical companies Kodiak Sciences Inc. (KOD), Repligen Corp. (RGEN) and Biogen Inc. (BIIB) surged to fresh 52-week highs on Monday amid positive trial results and strong earnings reports.KOD stock surged
EARNINGS | Sep 29, 2026, 04:24 AM UTC
L
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Shares of Kodiak Sciences (KOD) broke into September’s top five biotech gainers on a key eye drug win. Still, investor Martin Shkreli questioned whether it can outshine Eylea, Regeneron’s established treatment for wet ag
EQUITY | Sep 29, 2026, 02:13 AM UTC
H
MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing and Nvidia: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51,481.51, the S&P 500 slipping 0.77% to 7,683.69 and the Nasdaq declining 0.92% to 26,820.38. This market turbulence was
LIVE | Sep 29, 2026, 01:20 AM UTC
H
Gold Tumbles Over 3%; MongoDB Shares Move Lower
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Monday. The Dow traded down 0.50% to 51,571.80 while the NASDAQ dipped 0.63% to 26,897.56. The S&P 500 also fe
LIVE | Sep 28, 2026, 07:01 PM UTC
L
Kodiak Sciences Price Target Raised to $145.00/Share From $85.00 by LifeSci Capital
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 06:30 PM UTC
H
Dow Dips Over 200 Points; Dallas Fed’s Manufacturing Index Declines In September
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday. The Dow traded down 0.42% to 51,611.16 while the NASDAQ dipped 0.62% to 26,900.43. The S&P 500 also fell,
LIVE | Sep 28, 2026, 06:02 PM UTC
L
Kodiak Sciences Price Target Raised to $120.00/Share From $80.00 by UBS
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 05:38 PM UTC
L
Under the Radar: Kodiak Shares Surge as Eye Drug Matches Regeneron's — WSJ
By Xavier MartinezShares of Kodiak Sciences surged more than 170% Monday-on pace for its largest one-day increase on record-after the company announced its eye drug matched Regeneron's blockbuster Eylea in a Phase 3 tria
EQUITY | Sep 28, 2026, 05:36 PM UTC
L
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
Shares of Ocular Therapeutix (OCUL) dropped more than 22% on Monday as investors reacted to upbeat late-stage results from two competitors targeting the same crowded market for longer-lasting wet age-related macular dege
EQUITY | Sep 28, 2026, 05:16 PM UTC
L
Kodiak Sciences Price Target Raised to $96.00/Share From $58.00 by HC Wainwright & Co.
Ratings actions from Benzinga: GMT) Kodiak Sciences Is Maintained at Buy by HC Wainwright & Co.Ratings actions from Benzinga
NEWS | Sep 28, 2026, 04:32 PM UTC
L
HC Wainwright & Co. maintains Buy rating on Kodiak Sciences, $96 price target
HC Wainwright & Co. maintained their Buy rating on Kodiak Sciences's stock with a price target of $96.00.The price target implies an upside of 196.8% from the Sep 25 close of $32.35.Key takeaways from the analyst noteStr
EQUITY | Sep 28, 2026, 04:21 PM UTC
L
This Biotech Company Added Nearly $3B To Its Market Cap Today — Here’s Why KOD Stock Is Ripping Today
Shares of Kodiak Sciences (KOD) more than doubled after the opening bell on Monday as both of its experimental therapies met the primary goal of a Phase 3 study in patients with wet age-related macular degeneration.Wet A
EQUITY | Sep 28, 2026, 02:14 PM UTC
L
Kodiak Sciences Shares Hit 52-Week High After Positive Phase 3 Trial
By Chris WackKodiak Sciences shares more than doubled Monday after the company said its Phase 3 study for Zenkuda and tabirafusp-ted met the primary endpoints for both drugs in patients with wet age-related macular degen
EQUITY | Sep 28, 2026, 02:13 PM UTC
L
Kodiak Sciences: Zenkuda and tabirafusp-ted meet primary endpoints in Phase 3 DAYBREAK
Kodiak Sciences announced Zenkuda and tabirafusp-ted met primary endpoints in the Phase 3 DAYBREAK trial for wet AMD.Key Highlights:Original SEC Filing: Kodiak Sciences Inc. [ KOD ] - 8-K - Sep. 28, 2026This is an AI-pow
REGULATION | Sep 28, 2026, 01:06 PM UTC
L
Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial — Barrons.com
By Mackenzie TatananniShares of Kodiak Sciences headed for their best session on record Monday after two experimental eye drugs succeeded in a late-stage trial, positioning the biopharmaceutical company to get its first
EQUITY | Sep 28, 2026, 11:31 AM UTC
L
Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Pivotal Daybreak Trial In Wamd, With Zenkuda Demonstrating A Potential New Standard-Of-Care Profile
Kodiak Sciences Inc. NASDAQ:KOD
NEWS | Sep 28, 2026, 10:35 AM UTC
L
Kodiak Sciences Shares Surge Ahead of Phase 3 Readout
By Elias SchisgallShares of Kodiak Sciences surged ahead of the company's planned readout of topline results from a Phase 3 study of an eye disease treatment.The stock was up 17% to $38 in after-hours trading on Friday.
EQUITY | Sep 25, 2026, 10:22 PM UTC
L
Kodiak Sciences Price Target Announced at $36.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 11:41 AM UTC
L
Kodiak Sciences posts business highlights and Q2 2026 results
Kodiak Sciences (KOD) announces recent business highlights alongside its second quarter 2026 financial results.
EARNINGS | Aug 13, 2026, 08:00 PM UTC
M
Kodiak Sciences Completes Enrollment In Phase 3 PEAK Trial
Kodiak Sciences completes enrollment in Phase 3 trial
EQUITY | Aug 06, 2026, 11:01 AM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC